

Designing the Future: AI's Role in Drug Delivery

Mani Sharma

 <http://orcid.org/0000-0003-4718-9843>

Department of Pharmaceutics, School of Pharmacy, Anurag University, Hyderabad, India

Abhiram Kumar

BITS, India

Rama Satya Sri Kotipalli

CSIR-CCMB, Hyderabad, India

Mohini Rawat

School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, India

ABSTRACT

Artificial Intelligence (AI) is transforming drug delivery and discovery, promising faster timelines, enhanced efficacy, and personalized treatments. AI has achieved significant advancements in cancer detection, cardiovascular theranostics, and bioinformatics. Machine learning algorithms expedite drug candidate identification by predicting efficacy and safety, streamlining drug development, and enabling precision therapies. AI-driven models also design nanoscale delivery systems for targeted drug release, minimizing side effects and maximizing efficacy. In personalized medicine, AI analyzes genomics, proteomics, and clinical data to identify biomarkers, predict treatment responses, and optimize therapeutic regimens, shifting from one-size-fits-all to tailored interventions based on individual genetic profiles.

1. INTRODUCTION

The integration of artificial intelligence (AI) into the pharmaceutical industry has emerged as a transformative force, significantly altering the landscape of drug discovery and delivery. The ability of AI-based algorithms to analyze vast datasets to discern patterns, make predictions, and optimize processes is revolutionizing how new drugs are developed and brought to market (Huanbutta et al., 2024; Jain et al., 2024). Traditional drug discovery and delivery methods have been characterized by lengthy timelines, high costs, and a high rate of failure, largely due to the complexities involved in understanding biological systems and the human body. However, the incorporation of AI stands to mitigate many of

DOI: 10.4018/407366

these challenges by enhancing efficiency, accuracy, and innovation in both domains. AI encompasses a range of methodologies, including machine learning (ML), deep learning (DL), and natural language processing (NLP), which are employed to process extensive datasets comprising chemical compounds, biological information, and clinical trial results (Oh et al., 2023). By leveraging these technologies, researchers can better predict the efficacy and safety of drug candidates much earlier in the development process. This can potentially reduce the drug development timeline, a crucial factor considering that it typically takes over a decade and costs billions of dollars to bring a new drug to market. Using AI algorithms, the pharmaceutical industry can streamline various stages of drug discovery, from early-stage identification of viable drug candidates to optimization of lead compounds, enhancing the probability of success in clinical trials. One of the most notable advantages of AI is its capacity to improve the accuracy of predictive models in identifying novel drug candidates. By dissecting data from previous research and existing libraries of chemical compounds, AI systems can uncover relationships between molecular structures and biological activity. For example, deep learning models have been successfully utilized to predict the binding affinity of drugs to their target proteins, which is essential for understanding the drug's mechanism of action. These models harness the complexity of biological data and provide insights that are often inaccessible through traditional experimental methods. By doing so, they enable researchers to focus on the most promising candidates while bypassing less viable options early in the process (Fernandez, 2020).

Moreover, AI can significantly enhance the identification of potential drug interactions and toxicities, improving safety profiles. In traditional methods, recognizing adverse effects often requires extensive trial-and-error. AI-based systems, with their ability to analyze immense datasets, can flag potential issues before clinical trials begin, thereby saving time and resources (Al-Ashwal et al., 2023). For instance, machine learning algorithms can be trained on existing databases of known drug interactions to predict how new compounds might behave when combined with other medications. This capability is particularly vital in an era of personalized medicine, where patients often receive multiple treatments simultaneously. Ensuring the safety and efficacy of combinations is key to successful therapeutic outcomes. Alongside drug discovery, the role of AI extends into drug delivery mechanisms as well. Innovations in AI-driven methodologies can optimize how drugs are formulated and delivered to target sites in the body. For instance, researchers can use AI to create predictive models that determine the best delivery methods based on the characteristics of the drug and the nature of the target tissue. This could involve improving the design of nanoparticles or liposomes that encapsulate drugs, ensuring they reach their intended targets efficiently and effectively. Such advancements not only enhance the bioavailability of drugs but can also minimize side effects by reducing systemic exposure and associated complications (Kaladharan et al., 2024; Serrano et al., 2024).

Furthermore, AI's capabilities allow for real-time data monitoring and analysis, which is crucial for ensuring optimal delivery. During clinical trials, AI algorithms can evaluate the pharmacokinetics and pharmacodynamics of drugs in real time, adjusting treatment protocols based on individual patient responses. This level of personalized care is becoming increasingly important as we move towards more tailored therapeutic strategies, where treatments are adapted to fit the unique genetic and metabolic profiles of patients. Another critical aspect of AI in drug discovery and delivery is its potential for collaboration within the pharmaceutical ecosystem. By integrating AI-driven insights with expertise from various stakeholders—including bioinformaticians, medicinal chemists, and clinicians—researchers can foster a collaborative environment that accelerates innovation. Partnerships between AI technology companies and pharmaceutical firms are becoming more common, pooling resources and

20 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/designing-the-future/407366

Related Content

AI-Enhanced Neurophysiological Assessment

Deepak Kumar, Punet Kumar, Sushma Paland Sangam Singh (2025). *Transforming Neuropsychology and Cognitive Psychology With AI and Machine Learning* (pp. 33-64).

www.irma-international.org/chapter/ai-enhanced-neurophysiological-assessment/367703

Designing an AI Supported Teaching Module With STEM Approach for Science Education

Nagihan Kadolu, layda Saynand Özge Özyalçın Oskay (2026). *Ethical, Legal, and Pedagogical Perspectives on AI in Education* (pp. 277-300).

www.irma-international.org/chapter/designing-an-ai-supported-teaching-module-with-stem-approach-for-science-education/400181

Customer Journey Analysis: Insights From a Quantitative Approach on Consumer Behavior Across Touch points

Mahima Dogra, Pawan Kumarand Chahat Sahni (2026). *Harnessing AI for Point-of-Sale Optimization* (pp. 97-118).

www.irma-international.org/chapter/customer-journey-analysis/397980

Random Acquisition in Compressive Sensing: A Comprehensive Overview

Mahdi Khosravy, Thales Wulfert Cabral, Max Mateus Luiz, Neeraj Guptaand Ruben Gonzalez Crespo (2021). *International Journal of Ambient Computing and Intelligence* (pp. 140-165).

www.irma-international.org/article/random-acquisition-in-compressive-sensing/279589

Design and Implementation of BIOLOID Humanoid Robot

Hilberto Ayalaand Yujian Fu (2017). *Artificial Intelligence: Concepts, Methodologies, Tools, and Applications* (pp. 228-244).

www.irma-international.org/chapter/design-and-implementation-of-bioloid-humanoid-robot/173337